| Literature DB >> 29665373 |
Tatsuhiko Ozawa1, Hideyuki Masaki2, Tomohiko Takasaki3, Ikuko Aoyama4, Takahiro Yumisashi4, Atsushi Yamanaka5, Eiji Konishi5, Yoh Ohnuki1, Atsushi Muraguchi1, Hiroyuki Kishi6.
Abstract
West Nile virus (WNV) is a positive-sense single-stranded RNA flavivirus belonging to the Japanese encephalitis virus (JEV) serocomplex of the Flaviviridae family and causes mosquito-borne infections. Although most human infection cases are asymptomatic, approximately one in 150 infected individuals develops meningoencephalitis, with a mortality rate of 4-14%. While the development of human neutralizing antibody therapeutics against WNV is strongly anticipated, WNV is difficult to study in conventional laboratories due to its high safety level requirement. In this study, we established fully human WNV-neutralizing monoclonal antibodies from the peripheral blood mononuclear cells of inactivated-JEV-vaccinated individuals, and these antibodies exhibited WNV neutralization both in vitro and in vivo. Our results demonstrate a new antibody cross-reactivity strategy to develop immunological therapeutic reagents for WNV and other JEV serotype viruses.Entities:
Keywords: Human monoclonal antibody; Japanese encephalitis virus; Neutralization antibody; Vaccination; West Nile virus
Mesh:
Substances:
Year: 2018 PMID: 29665373 DOI: 10.1016/j.antiviral.2018.04.011
Source DB: PubMed Journal: Antiviral Res ISSN: 0166-3542 Impact factor: 5.970